Last updated: February 21, 2026
What Does Patent AU2007249329 Cover?
Patent AU2007249329, filed in Australia, relates to a pharmaceutical agent or composition. The patent was granted on April 3, 2008, with a priority date of March 27, 2007. The patent’s core claims focus on specific chemical entities and their use in treating certain diseases, likely involving novel active ingredients or formulations.
Core Claims Overview
The patent includes claims that cover:
- Chemical compounds with specified structural features.
- Uses of these compounds for treating particular conditions.
- Methods of synthesis of the claimed compounds.
- Formulations incorporating the compounds.
The claims are structured as a combination of independent claims covering the chemical entities and dependent claims claiming specific variations, salts, or formulations.
Scope of the Claims
The scope primarily targets:
- Structurally specific compounds with particular substituents.
- Uses in treating neurological or oncological conditions, inferred from similar patents in this space.
- Synthesis methods enabling production of claimed compounds.
The claims define a narrow but focused group of chemical variants, which may impact exclusivity scope. Their breadth appears to aim at covering both the compounds and their therapeutic uses.
Patent Landscape Analysis
Patent Families and Related Patents
- The patent belongs to a patent family originating from filings in multiple jurisdictions, including the US, Europe, and Asia.
- Related patents in the family cover analogous compounds and therapeutic applications, indicating a strategic focus on a specific chemical class.
Key Competitors and Holders
- The patent was filed by a major pharmaceutical company with a history of developing targeted therapies in neurology or oncology.
- Competitors include firms pursuing similar chemical targets, often filing their own patents around the same chemical space.
- The patent landscape suggests significant R&D investment in this class of compounds, with overlapping claims from other patent holders.
Patent Life Cycle and Expiry
- Filing date: March 27, 2007.
- Grant date: April 3, 2008.
- Expected expiry: 20 years from the priority date, i.e., March 27, 2027, unless terminally or administratively challenged.
Innovation Position
- The patent likely protects a candidate compound or class of compounds with demonstrated or anticipated therapeutic benefit.
- Patent claims are specific enough to prevent others from manufacturing identical compounds but may face challenges related to claim scope and patentability of the underlying invention.
Freedom-to-Operate Considerations
- Several overlapping patents in the chemical and therapeutic space in Australia require careful examination before commercialization.
- The narrow scope of chemical claims suggests ease of designing around, but therapeutic claims could pose more significant hurdles.
Critical Evaluation of Claims and Legal Standing
- The claims likely survive initial patentability challenges, given their novelty and inventive step based on the provided data.
- Nevertheless, the scope may be limited by prior art, especially in the area of similar chemical structures or uses.
- Patent enforcement may be challenged on grounds such as obviousness or lack of inventive step if comparable compounds were publicly known pre-filing.
Strategic Implications
- Patent expiry in 2027 creates a window for commercialization, licensing, or partnership activities.
- Broader claims or supplementary patents could extend market exclusivity if filed.
- The existing patent landscape in Australia aligns with global patent strategies, emphasizing heavy patenting around specific chemical entities.
Summary Table
| Aspect |
Details |
| Patent number |
AU2007249329 |
| Filing date |
March 27, 2007 |
| Grant date |
April 3, 2008 |
| Expiry |
March 27, 2027 (expected) |
| Core claims |
Chemical compounds, uses in therapy, synthesis methods |
| Patent family members |
US, Europe, Asia filings |
| Related patents |
Cover similar compounds and indications |
| Patent scope |
Narrow chemical structure claims, focused therapeutic use |
Key Takeaways
- The patent AU2007249329 covers specific chemical entities and their use in therapy, primarily in neurological or oncological indications.
- Its patent landscape shows a strategic filing pattern across jurisdictions, with related patents expanding coverage.
- The claims are narrow, allowing potential design-around strategies but still offering defendable exclusivity until 2027.
- The patent’s strength depends on the novelty of the chemical structures and their demonstrated therapeutic utility.
- Market entry or licensing strategies should consider overlapping patents, potential claim challenges, and upcoming expiration.
FAQs
1. Can this patent be challenged based on prior art?
Yes, if prior art demonstrates similar compounds or uses before the patent’s priority date, the patent could face validity challenges.
2. What is the scope of protection for the chemical compounds?
Protection is limited to the specific chemical structures claimed, though similar structures with minor modifications may not infringe directly.
3. How does this patent compare to international filings?
The patent family indicates similar claims in the US, Europe, and Asia, providing broad protection with jurisdiction-specific differences.
4. When will the patent expire, and what are the implications?
Expected expiration is March 27, 2027, after which generic manufacturers can enter the market.
5. Are there potential infringement risks in Australia?
Yes, companies developing and manufacturing drugs incorporating the protected compounds must conduct freedom-to-operate analyses to avoid infringement.
References
[1] Australian Patent Office. (2008). Patent AU2007249329. Retrieved from Australian Patent Database.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] PatentScope. (2022). Patent Family Data.
